Company Overview and News

 
Paramount Gold Nevada Corp. to Present at the European Gold Forum in Zurich

2018-04-16 globenewswire
WINNEMUCCA, Nev., April 16, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American:PZG) ("Paramount”) announced today that its CEO, Glen Van Treek will be presenting at the European Gold Forum on Thursday April 19, 2018 at 11:00 AM Local Time in Ballroom 2 of the Park Hyatt Hotel in Zurich, Switzerland.
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. 10-Q (Quarterly Report)

2018-02-08 sec.gov
pzg-10q_20171231.htm UNITED STATES
Upvote Downvote

 
Paramount Gold Nevada (PZG) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - Slideshow

2018-01-31 seekingalpha
The following slide deck was published by Paramount Gold Nevada Corp. in conjunction with this event.
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. / FCMI FINANCIAL CORP ET AL - SC 13G/A (Passive Investment)

2018-01-24 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549    SCHEDULE 13G (Rule 13d-102)    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)*    PARAMOUNT GOLD NEVADA CORP. (Name of Issuer)    Common Shares, par value US$ 0.01 per share (Title of Class of Securities)    69924M 109 (CUSIP Number)                                      December 31, 2017                                    (Dat
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. / FCMI FINANCIAL CORP ET AL - SC 13G/A (Passive Investment)

2018-01-24 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549    SCHEDULE 13G (Rule 13d-102)    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)*    PARAMOUNT GOLD NEVADA CORP. (Name of Issuer)    Common Shares, par value US$ 0.01 per share (Title of Class of Securities)    69924M 109 (CUSIP Number)                                      December 31, 2017                                    (Dat
Upvote Downvote

12
Top 20 Gold Mining Stocks For 2018

2018-01-02 seekingalpha
Above are my Top 20 gold mining stocks for 2018. All of these companies have large resources and are highly undervalued based on their cash flow potential at higher gold prices. They are on this list primarily because of their upside potential. These are either producers or development stocks, although there is one optionality play (Goldmining Inc).
Upvote Downvote

4
Stocks To Watch: Automakers Rev Up For 2018

2017-12-31 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning.
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. 8-K - 2017 AGM (Current Report)

2017-12-13 sec.gov
pzg-8k_20171214.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):  December 13, 2017   PARAMOUNT GOLD NEVADA CORP. (Exact name of registrant as specified in its charter)   Nevada (State or Other Jurisdiction of Incorporation)         001-36908   98-0138393 (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

1
It's Time To Buy Junior Gold Miners Again

2017-12-12 seekingalpha
A combination of seasonal weakness, tax-loss selling, and an impending Fed rate hike have driven down the gold price and the stock prices of gold miners.
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. 8-K (Current Report)

2017-11-29 sec.gov
pzg-8k_20171129.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):  November 29, 2017   PARAMOUNT GOLD NEVADA CORP. (Exact name of registrant as specified in its charter)   Nevada (State or Other Jurisdiction of Incorporation)         001-36908   98-0138393 (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. 10-Q (Quarterly Report)

2017-11-07 sec.gov
pzg-10q_20170930.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q   (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO Commission File Number 001-36908   PARAMOUNT GOLD NEVADA CORP.
Upvote Downvote

 
Paramount Gold Nevada DEF 14A - 2017

2017-10-28 sec.gov
pzg-def14a_20171213.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to
Upvote Downvote

 
Paramount Gold Nevada DEFA14A

2017-10-28 sec.gov
pzg-defa14a_20171027.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting M
Upvote Downvote

 
Paramount Gold Nevada 3D/A (Activist Acquisition of More Than 5% of Shares)

2017-10-18 sec.gov
  SCHEDULE 13D   CUSIP NO: 69924M 109  PAGE 1 of 5     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934   PARAMOUNT GOLD NEVADA CORP. (Name of Issuer)   Common Stock, par value US$ 0.01 per share  (Title of Class of Securities)   69924M 109  (CUSIP Number)   Guy Ben Ami  Carter Ledyard & Milburn LLP 2 Wall Street, New York, New York 10005 212-238-8658  (Name, Address and Telephone Number of Person
Upvote Downvote

 
PZG / Paramount Gold Nevada Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-10-18 fintel.io
Paramount Gold Nevada Corp. (AMEX:PZG) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,316,860 shares. Largest shareholders include Seabridge Gold Inc, Advisor Group, Inc., Vanguard Group Inc, Renaissance Technologies LLC, and Geode Capital Management, Llc.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 69924M109